Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibition
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.218046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Yanbin Kuang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Sha…. Hauptthemen laut MEDLINE: Ferroptosis, Tropolone, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit nennt 77 Literaturangaben. Gefördert von: Shanghai Chest Hospital, Shanghai Rising-Star Program, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Dysregulated ISC metabolism has been implicated in cancer progression, but its role in LUAD pathogenesis and therapeutic targeting remains poorly understood. Here, we demonstrate that ISC biogenesis is significantly upregulated in LUAD, driven by transcription factors KLF15 and ZNF384, which activate GLRX5, LYRM4, NFS1 and BOLA3 promoters. IL-1β promotes PCAF mitochondrial translocation, releasing EP300 to amplify KLF15/ZNF384-mediated transcriptional activation. The natural monoterpenoid Hinokitiol inhibits LUAD growth by disrupting EP300-KLF15/ZNF384 interactions, suppressing ISC biogenesis gene expression and inducing ferroptosis. Mechanistically, the membrane protein TMDD1, particularly its cytoplasmic domain, promotes Hinokitiol's anti-tumor effects by facilitating EP300-KLF15/ZNF384 dissociation and inhibiting ISC biogenesis. Remarkably, Hinokitiol exhibits stage-dependent efficacy, with superior suppression of metastatic (stage IV) tumors linked to heightened ferroptosis sensitivity. This study not only elucidates the transcriptional machinery governing ISC biogenesis in LUAD but also highlights Hinokitiol's dual mechanism as a promising stage-specific therapeutic agent, offering novel strategies for advanced disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hosp…
- Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: 18930858216@163.com.
- Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: zhwei2002@sjtu.edu.cn.
Förderung
- Shanghai Chest Hospital
- Shanghai Rising-Star Program
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Kuang, Y., Yang, S., Tian, X., Cheng, H., Liu, B., Zhang, C., Han, B., Zhang, W., Zhang, X., & Lou, Y. (2025). Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibition. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218046
Vancouver
Kuang Y, Yang S, Tian X, Cheng H, Liu B, Zhang C, et al. Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibition. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218046
BibTeX
@article{Kuang2025,
author = {Kuang, Yanbin and Yang, Suyang and Tian, Xiaoting and Cheng, Huiyan and Liu, Beibei and Zhang, Congcong and Han, Baohui and Zhang, Wei and Zhang, Xiao and Lou, Yuqing},
title = {Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibition},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.218046}
}
EUVIMED